Korro Bio
Update in progressKRRO (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Korro Bio is a biopharmaceutical company developing RNA editing therapies to treat rare and common diseases in the United States. Its lead candidate, KRRO-121, targets hyperammonemia. The company uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA, to create differentiated product candidates. It also explores programs for Parkinson’s disease, ALS, anesthesia-related pain, and other indications, and has a collaboration with Novo Nordisk for cardiometabolic diseases. Founded in 2018, it is based in Cambridge, Massachusetts.
Company score
- Sentiment
- 0.18
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.00
- Governance
- 0.19
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.04
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.11
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!